FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Inc, maker of Botox, said on Friday that the U.S.
Originally posted here:
FDA Approves Allergan’s Drug for Longer Eyelashes
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…
IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc.
FDA OKs 1st Eyelash Drug Latisse
Title: FDA OKs 1st Eyelash Drug LatisseCategory: Health NewsCreated: 12/29/2008Last Editorial Review: 12/29/2008 (Source: MedicineNet Eyesight General) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network , and receive $5 free advertising.
Continued here:
FDA OKs 1st Eyelash Drug Latisse
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
New prescription drug Latisse increases the length, thickness and darkness of eyelashes. (Source: Huliq Health News)
See the original post here:
FDA OKs Latisse For Hypotrichosis of Eyelashes Treatment
Allergan Eyelash Enhancer Approved
Allergan received FDA approval to market Latisse, a beauty treatment that increases the length, thickness and darkness of eyelashes by using a drug the company developed to treat glaucoma. (Source: WSJ.com: Health)
Go here to read the rest:
Allergan Eyelash Enhancer Approved
Allergan Gets Nod For Eyelash Treatment
Eye care and cosmetic drug maker Allergan on Friday said its eyelash growth treatment Latisse received Food and Drug Administration approval,… (Source: Investor’s Business Daily: HEALTH)
Original post:
Allergan Gets Nod For Eyelash Treatment
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on New Aesthetic Opportunities
(Source: Modern Medicine)
Excerpt from:
(sponsored multimedia) Latisse™ (bimatoprost ophthalmic solution) 0.03%: A National Summit on
New Aesthetic Opportunities
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc.
